CN111759814A - Fludrocortisone acetate tablet for resisting inflammation and processing technology - Google Patents
Fludrocortisone acetate tablet for resisting inflammation and processing technology Download PDFInfo
- Publication number
- CN111759814A CN111759814A CN202010700674.8A CN202010700674A CN111759814A CN 111759814 A CN111759814 A CN 111759814A CN 202010700674 A CN202010700674 A CN 202010700674A CN 111759814 A CN111759814 A CN 111759814A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactose
- fludrocortisone acetate
- type
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 title claims abstract description 44
- 229960003336 fluorocortisol acetate Drugs 0.000 title claims abstract description 44
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 15
- 238000005516 engineering process Methods 0.000 title abstract description 10
- 238000012545 processing Methods 0.000 title abstract description 10
- 230000004054 inflammatory process Effects 0.000 title abstract description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 82
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 44
- 239000008101 lactose Substances 0.000 claims abstract description 44
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 41
- 239000000314 lubricant Substances 0.000 claims abstract description 22
- 239000000945 filler Substances 0.000 claims abstract description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 20
- 229920002472 Starch Polymers 0.000 claims abstract description 20
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 20
- 239000011734 sodium Substances 0.000 claims abstract description 20
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 20
- 239000008107 starch Substances 0.000 claims abstract description 20
- 235000019698 starch Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000007908 dry granulation Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 sugar alcohol compounds Chemical class 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 6
- 238000011084 recovery Methods 0.000 abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a fludrocortisone acetate tablet for anti-inflammation and a processing technology thereof, wherein the tablet comprises the following raw materials in parts by weight: 0.005-0.015 part of fludrocortisone acetate, 2.1-2.3 parts of first lactose, 7.34-7.54 parts of second lactose, 0.15-0.35 part of A-type carboxymethyl starch sodium, 0.04-0.06 part of I-type magnesium stearate, 0.04-0.06 part of II-type magnesium stearate, 6-10 parts of filler and 1-3 parts of lubricant, wherein the raw materials comprise the following components in parts by weight: the invention relates to the technical field of fludrocortisone acetate, and discloses the fludrocortisone acetate, which comprises 0.01 part of fludrocortisone acetate, 2.20 parts of first lactose, 7.44 parts of second lactose, 0.25 part of A-type carboxymethyl starch sodium and 0.05 part of I-type magnesium stearate. According to the fludrocortisone acetate tablet for resisting inflammation and the processing technology, the fludrocortisone acetate, the first lactose, the second lactose, the A-type carboxymethyl starch sodium, the I-type magnesium stearate, the II-type magnesium stearate, the filler and the lubricant are mixed for pharmacy, so that the tablet is stronger in anti-inflammation, and compared with a conventional anti-inflammatory drug, the tablet is quick in effect taking and shorter in recovery period after being used.
Description
Technical Field
The invention relates to the technical field of fludrocortisone acetate, in particular to a fludrocortisone acetate tablet for resisting inflammation and a processing technology thereof.
Background
Dermatitis is complex in etiology and may be associated with the following factors: 1. internal factors: it is related to chronic infection focus, endocrine and metabolism change, blood circulation disorder, neuropsychiatric factors, genetic factors, etc. 2. External factors: can be induced or aggravated by foods such as fish, shrimp, beef and mutton, inhalants such as pollen, dust mite, living environment such as cold, hot, dry, etc., animal fur, and various physicochemical substances such as cosmetics, soap, synthetic fiber, etc., and the existing dermatosis such as allergic dermatitis, contact dermatitis, seborrheic dermatitis, eczema, etc. can bring pain to patients and bring inconvenience to life.
Fludrocortisone acetate is mainly used for the replacement therapy of adrenocortical insufficiency, and can be externally used for treating dermatosis such as allergic dermatitis, contact dermatitis, seborrheic dermatitis, eczema and the like.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a fludrocortisone acetate tablet for resisting inflammation and a processing technology thereof.
In order to achieve the purpose, the invention is realized by the following technical scheme: the fludrocortisone acetate tablet for resisting inflammation comprises the following raw materials in parts by weight: 0.005-0.015 part of fludrocortisone acetate, 2.1-2.3 parts of first lactose, 7.34-7.54 parts of second lactose, 0.15-0.35 part of A-type carboxymethyl starch sodium, 0.04-0.06 part of I-type magnesium stearate, 0.04-0.06 part of II-type magnesium stearate, 6-10 parts of filler and 1-3 parts of lubricant.
Preferably, the raw materials comprise the following components in parts by weight: 0.01 part of fludrocortisone acetate, 2.20 parts of first lactose, 7.44 parts of second lactose, 0.25 part of A-type carboxymethyl starch sodium, 0.05 part of I-type magnesium stearate, 0.05 part of II-type magnesium stearate, 8 parts of filler and 2 parts of lubricant.
Preferably, the raw materials comprise the following components in parts by weight: 0.005 part of fludrocortisone acetate, 2.1 parts of first lactose, 7.34 parts of second lactose, 0.15 part of A-type carboxymethyl starch sodium, 0.04 part of I-type magnesium stearate, 0.04 part of II-type magnesium stearate, 6 parts of filler and 1 part of lubricant.
Preferably, the lubricating agent comprises 0.015 part of fludrocortisone acetate, 2.3 parts of first lactose, 7.54 parts of second lactose, 0.35 part of A-type carboxymethyl starch sodium, 0.06 part of I-type magnesium stearate, 0.06 part of II-type magnesium stearate, 10 parts of a filling agent and 3 parts of a lubricating agent.
Preferably, the filler is a mixture of sugar alcohol compounds and microcrystalline cellulose, and the lubricant is one of magnesium stearate, sodium lauryl sulfate or hydrogenated vegetable oil.
Preferably, the first lactose has a size of 80 mesh and the second lactose has a size of 200 mesh.
The invention also discloses a processing technology of the fludrocortisone acetate tablet for resisting inflammation, and the preparation method specifically comprises the following steps:
step one, mixing type I magnesium stearate, fludrocortisone acetate and first lactose by a mixer for 10-20 min;
step two, adding the second lactose and the A-type carboxymethyl starch sodium into a mixer for mixing for 6-8 min;
adding type II magnesium stearate into a mixer, mixing for 3-5 min;
and step four, performing dry granulation on the mixed materials, and then preparing the obtained powdery solid, the filler and the lubricant by adopting a powder direct tabletting method.
The invention provides a fludrocortisone acetate tablet for resisting inflammation and a processing technology thereof. Compared with the prior art, the method has the following beneficial effects:
(1) the fludrocortisone acetate tablet for resisting inflammation and the processing technology are prepared by mixing fludrocortisone acetate, first lactose, second lactose, A-type carboxymethyl starch sodium, I-type magnesium stearate, II-type magnesium stearate, a filling agent and a lubricating agent, so that the tablet is stronger in anti-inflammation, and has a shorter recovery period after being used compared with a conventional anti-inflammatory drug.
Drawings
FIG. 1 is a statistical table of comparative experimental data according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, the embodiment of the present invention provides three technical solutions: a fludrocortisone acetate tablet for anti-inflammation and a processing technology thereof specifically comprise the following embodiments:
example 1
The raw materials comprise the following components in parts by weight: 0.01 part of fludrocortisone acetate, 2.20 parts of first lactose, 7.44 parts of second lactose, 0.25 part of A-type carboxymethyl starch sodium, 0.05 part of I-type magnesium stearate, 0.05 part of II-type magnesium stearate, 8 parts of filler and 2 parts of lubricant.
The preparation method specifically comprises the following steps:
step one, mixing 0.05 part of type I magnesium stearate, 0.01 part of fludrocortisone acetate and 2.20 parts of first lactose by a mixer for 15 min;
step two, adding 7.44 parts of second lactose and 0.25 part of A-type carboxymethyl starch sodium into a mixer for mixing for 7 min;
adding 0.05 part of type II magnesium stearate into a mixer, mixing for 4 min;
and step four, performing dry granulation on the mixed materials, and then preparing the obtained powdery solid, 8 parts of filler and 2 parts of lubricant by adopting a powder direct tabletting method.
Example 2
0.005 part of fludrocortisone acetate, 2.1 parts of first lactose, 7.34 parts of second lactose, 0.15 part of A-type carboxymethyl starch sodium, 0.04 part of I-type magnesium stearate, 0.04 part of II-type magnesium stearate, 6 parts of filler and 1 part of lubricant.
The preparation method specifically comprises the following steps:
step one, mixing 0.04 parts of type I magnesium stearate, 0.005 parts of fludrocortisone acetate and 2.1 parts of first lactose by a mixer for 15 min;
step two, adding 7.34 parts of second lactose and 0.15 part of A-type carboxymethyl starch sodium into a mixer for mixing for 7 min;
adding 0.04 part of type II magnesium stearate into a mixer, mixing for 4 min;
and step four, performing dry granulation on the mixed materials, and then preparing the obtained powdery solid, 6 parts of filler and 1 part of lubricant by adopting a powder direct tabletting method.
Example 3
0.015 part of fludrocortisone acetate, 2.3 parts of first lactose, 7.54 parts of second lactose, 0.35 part of A-type carboxymethyl starch sodium, 0.06 part of I-type magnesium stearate, 0.06 part of II-type magnesium stearate, 10 parts of filler and 3 parts of lubricant.
The preparation method specifically comprises the following steps:
step one, mixing 0.06 part of type I magnesium stearate, 0.015 part of fludrocortisone acetate and 2.3 parts of first lactose by a mixer for 15 min;
step two, adding 7.54 parts of second lactose and 0.35 part of A-type carboxymethyl starch sodium into a mixer for mixing for 7 min;
adding 0.06 part of type II magnesium stearate into a mixer, mixing for 4 min;
and step four, performing dry granulation on the mixed materials, and then preparing the obtained powdery solid, 10 parts of filler and 3 parts of lubricant by adopting a powder direct tabletting method.
Comparative experiment
In a certain medical laboratory, 20 dermatitis patients are selected as volunteers, have no hypertension, liver disease and myxoedema, are not in the gestational period, and are respectively subjected to the medical test determination of example 1, example 2 and example 3 by taking a conventional fludrocortisone acetate tablet as a comparative example, 5 patients are taken as each example, and the recovery period and the erythema edema condition after one week of use are counted;
as shown in the table 1, the fludrocortisone acetate tablet for anti-inflammation helps the patient to recover, and the recovery period is shorter.
And those not described in detail in this specification are well within the skill of those in the art.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. A fludrocortisone acetate tablet for anti-inflammation is characterized in that: the raw materials comprise the following components in parts by weight: 0.005-0.015 part of fludrocortisone acetate, 2.1-2.3 parts of first lactose, 7.34-7.54 parts of second lactose, 0.15-0.35 part of A-type carboxymethyl starch sodium, 0.04-0.06 part of I-type magnesium stearate, 0.04-0.06 part of II-type magnesium stearate, 6-10 parts of filler and 1-3 parts of lubricant.
2. The fludrocortisone acetate tablet for anti-inflammatory of claim 1, further comprising: the raw materials comprise the following components in parts by weight: 0.01 part of fludrocortisone acetate, 2.20 parts of first lactose, 7.44 parts of second lactose, 0.25 part of A-type carboxymethyl starch sodium, 0.05 part of I-type magnesium stearate, 0.05 part of II-type magnesium stearate, 8 parts of filler and 2 parts of lubricant.
3. The fludrocortisone acetate tablet for anti-inflammatory of claim 1, further comprising: the raw materials comprise the following components in parts by weight: 0.005 part of fludrocortisone acetate, 2.1 parts of first lactose, 7.34 parts of second lactose, 0.15 part of A-type carboxymethyl starch sodium, 0.04 part of I-type magnesium stearate, 0.04 part of II-type magnesium stearate, 6 parts of filler and 1 part of lubricant.
4. The fludrocortisone acetate tablet for anti-inflammatory of claim 1, further comprising: the raw materials comprise the following components in parts by weight: 0.015 part of fludrocortisone acetate, 2.3 parts of first lactose, 7.54 parts of second lactose, 0.35 part of A-type carboxymethyl starch sodium, 0.06 part of I-type magnesium stearate, 0.06 part of II-type magnesium stearate, 10 parts of filler and 3 parts of lubricant.
5. The fludrocortisone acetate tablet for anti-inflammatory of claim 1, further comprising: the filler is a mixture of sugar alcohol compounds and microcrystalline cellulose, and the lubricant is one of magnesium stearate, sodium dodecyl sulfate or hydrogenated vegetable oil.
6. The fludrocortisone acetate tablet for anti-inflammatory of claim 1, further comprising: the first lactose is 80 meshes in size, and the second lactose is 200 meshes in size.
7. The fludrocortisone acetate tablet for anti-inflammatory according to any of claims 1 to 6, further comprising: the preparation method specifically comprises the following steps:
step one, mixing type I magnesium stearate, fludrocortisone acetate and first lactose by a mixer for 10-20 min;
step two, adding the second lactose and the A-type carboxymethyl starch sodium into a mixer for mixing for 6-8 min;
adding type II magnesium stearate into a mixer, mixing for 3-5 min;
and step four, performing dry granulation on the mixed materials, and then preparing the obtained powdery solid, the filler and the lubricant by adopting a powder direct tabletting method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010700674.8A CN111759814A (en) | 2020-07-20 | 2020-07-20 | Fludrocortisone acetate tablet for resisting inflammation and processing technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010700674.8A CN111759814A (en) | 2020-07-20 | 2020-07-20 | Fludrocortisone acetate tablet for resisting inflammation and processing technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111759814A true CN111759814A (en) | 2020-10-13 |
Family
ID=72728531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010700674.8A Pending CN111759814A (en) | 2020-07-20 | 2020-07-20 | Fludrocortisone acetate tablet for resisting inflammation and processing technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111759814A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109602728A (en) * | 2019-01-18 | 2019-04-12 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral quick-dissolving film preparation and preparation method thereof |
| CN109662949A (en) * | 2017-10-16 | 2019-04-23 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral disnitegration tablet and preparation method thereof |
| WO2019175703A1 (en) * | 2018-03-12 | 2019-09-19 | Syri Ltd | Stable liquid suspension composition of fludrocortisone |
-
2020
- 2020-07-20 CN CN202010700674.8A patent/CN111759814A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109662949A (en) * | 2017-10-16 | 2019-04-23 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral disnitegration tablet and preparation method thereof |
| WO2019175703A1 (en) * | 2018-03-12 | 2019-09-19 | Syri Ltd | Stable liquid suspension composition of fludrocortisone |
| CN109602728A (en) * | 2019-01-18 | 2019-04-12 | 江苏福锌雨医药科技有限公司 | A kind of fludrocortisone acetate oral quick-dissolving film preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| HTTP:https://ZY.YAOZH.COM/DATA/PDF/00055056.PDF: "《醋酸氟氢可的松片剂说明书》", 30 September 2017 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jarrett et al. | Diurnal variation in oral glucose tolerance: blood sugar and plasma insulin levels morning, afternoon, and evening | |
| CN104146976A (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| CN104640544A (en) | Therapeutic agent for dyslipidemia | |
| CN110898025A (en) | Acarbose sustained-release preparation and preparation method thereof | |
| CN113018273A (en) | Solid preparation and preparation method and application thereof | |
| JP2023134691A (en) | Modified release pharmaceutical compositions of huperzine, and methods of using the same | |
| CN111759814A (en) | Fludrocortisone acetate tablet for resisting inflammation and processing technology | |
| CN101953814A (en) | Febuxostat solid preparation | |
| CN103655505A (en) | Pain relieving bilayer controlled-release tablet and preparation method thereof | |
| JP7553728B2 (en) | Use of high-dose modified-release huperzine formulations | |
| Iwakiri et al. | Association between renal vasculature changes and generalized atherosclerosis: an autopsy survey | |
| DE102017105036A1 (en) | Agent for use in the treatment of dyslipidemia | |
| CN117717532A (en) | Epalrestat gastric floating tablet, and preparation method and application thereof | |
| CN106214653A (en) | A kind of FCE-26743A slow releasing tablet and preparation method thereof | |
| CN111741753A (en) | Method for treating hypertriglyceridemia | |
| CN101642442B (en) | Tablets for preventing and curing osteoarthritis and preparation method thereof | |
| CN1579401A (en) | Cought and asthma relieaving preparation and its preparation method | |
| CN109316454B (en) | Calcitriol preparation | |
| CN102008466A (en) | Febuxostat medicament composition and preparation method thereof | |
| CN106924270A (en) | A kind of pharmaceutical composition with weight losing function containing orlistat | |
| CN1287860C (en) | Combination of medication containing reductase inhibitor HMG CoA and Melatonin | |
| CN107648229B (en) | A kind of Febustat composition | |
| CN105307653A (en) | Therapeutic agent for dyslipidemia | |
| Schwenke et al. | Tapentadol prolonged release as used in clinical practice in patients with severe chronic tumor pain | |
| JP2008214230A (en) | Method for treating mammal with extract of ganoderma lucidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201013 |